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1200Objective: Normothermic ex vivo lung perfusion is a novel method to evaluate and improve the function of in-
jured donor lungs. We reviewed our experience with 50 consecutive transplants after ex vivo lung perfusion.
Methods: A retrospective study using prospectively collected data was performed. High-risk brain death donor
lungs (defined as PaO2/FIO2<300 mm Hg or lungs with radiographic or clinical findings of pulmonary edema)
and lungs from cardiac death donors were subjected to 4 to 6 hours of ex vivo lung perfusion. Lungs that
achieved stable airway and vascular pressures and PaO2/FIO2 greater than 400 mm Hg during ex vivo lung per-
fusion were transplanted. The primary end point was the incidence of primary graft dysfunction grade 3 at 72
hours after transplantation. End points were compared with lung transplants not treated with ex vivo lung per-
fusion (controls).
Results:A total of 317 lung transplants were performed during the study period (39 months). Fifty-eight ex vivo
lung perfusion procedures were performed, resulting in 50 transplants (86% use). Of these, 22 were from cardiac
death donors and 28 were from brain death donors. The mean donor PaO2/FIO2 was 334 mm Hg in the ex vivo
lung perfusion group and 452 mm Hg in the control group (P¼ .0001). The incidence of primary graft dysfunc-
tion grade 3 at 72 hours was 2% in the ex vivo lung perfusion group and 8.5% in the control group (P¼ .14). One
patient (2%) in the ex vivo lung perfusion group and 7 patients (2.7%) in the control group required extracor-
poreal lung support for primary graft dysfunction (P¼ 1.00). The median time to extubation, intensive care unit
stay, and hospital length of stay were 2, 4, and 20 days, respectively, in the ex vivo lung perfusion group and 2, 4,
and 23 days, respectively, in the control group (P>.05). Thirty-day mortality (4% in the ex vivo lung perfusion
group and 3.5% in the control group, P¼ 1.00) and 1-year survival (87% in the ex vivo lung perfusion group and
86% in the control group, P ¼ 1.00) were similar in both groups.
Conclusions: Transplantation of high-risk donor lungs after 4 to 6 hours of ex vivo lung perfusion is safe, and
outcomes are similar to those of conventional transplants. Ex vivo lung perfusion improved our center use of
donor lungs, accounting for 20% of our current lung transplant activity. (J Thorac Cardiovasc Surg
2012;144:1200-7)Lung transplantation (LTx) is often the only treatment op-
tion for patients with end-stage lung disease, who will oth-
erwise die. Despite significant advances made since the first
clinically successful LTx in 1983, LTx clinicians still face
some challenges. The first major obstacle is the short supply
of donor organs. As the population ages, the number of pa-
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The Journal of Thoracic and Cardiovascular Surdonor lungs has remained essentially static. Furthermore,
the situation is aggravated by a low use rate of 15% to
20% of offered donor organs.1 This conservative use stems
from the vulnerability of the donor lung to injury during the
brain death process or during intensive care unit (ICU) man-
agement.2 Whereas management strategies in the multior-
gan donor are important in preventing lung deterioration,3
organ retrieval often has to occur before the lungs have
time to recover from brain death or other related injuries.4
Although maintaining organ viability using static hypo-
thermic preservation is the widely accepted method of pre-
serving donor lung viability after removal,5,6 the inhibition
of cellular metabolism induced by hypothermia7 hinders the
process of recovery and negates the possibility of assess-
ment (testing the organ before transplant) or repair during
the organ preservation period. In 2001, Steen and col-
leagues8 described the first transplantation after normother-
mic ex vivo assessment of a donor lung from a cardiac death
donor (DCD). Since 2006, our group in Toronto has made
significant modifications to the ex vivo lung perfusiongery c November 2012
Abbreviations and Acronyms
BDD ¼ brain death donor
DCD ¼ cardiac death donor
ECLS ¼ extracorporeal life support
EVLP ¼ ex vivo lung perfusion
ICU ¼ intensive care unit
LTx ¼ lung transplantation
P/F ¼ PaO2/FIO2
PGD ¼ primary graft dysfunction
Cypel et al Cardiothoracic Transplantation(EVLP) strategy, system, and technique. After extensive
laboratory research, we performed the first prospective clin-
ical trial of EVLP including 20 patients, demonstrating the
safety of the procedure.9 We report our experience with 50
consecutive lung transplants after 4 to 6 hours of EVLP of
high-risk donor lungs.T
XMATERIALS AND METHODS
Study Design
This is a single-institution, retrospective study using prospectively col-
lected data. Outcomes of consecutive recipients undergoing transplanta-
tion after normothermic EVLP of high-risk donor lungs10 were studied
and compared with those of contemporary conventional LTx recipients.
Donor lungs that met study entry criteria were retrieved in a standard fash-
ion, transported from the donor hospital to our center under standard con-
ditions of cold storage in a low potassium dextran solution (Perfadex;
Vitrolife, Gothenburg, Sweden), and placed in the EVLP system. The or-
gans were then perfused for 4 to 6 hours with hourly functional assess-
ments. Lungs with a PaO2/FIO2 (P/F) of 400 mm Hg or greater and
stable or improving pulmonary artery pressure, airway pressures, or dy-
namic compliance were considered transplantable. Lungs were excluded
for transplantation if the P/F was less than 400 mm Hg or they demon-
strated greater than 15% deterioration in the other functional parameters
noted earlier.
Care after LTx, including fluid management, antibiotic prophylaxis, im-
munosuppression regimens, and surveillance bronchoscopy, was per-
formed for both groups according to current standard practice at the
University of Toronto.11
Donors
High-risk donor lungs were defined as those that had any of the fol-
lowing: (1) best P/F less than 300 mm Hg; (2) pulmonary edema detected
on the last chest x-ray or during clinical examination of the lungs; (3)
poor lung compliance during examination of the lungs during donor op-
eration; (4) donation after cardiac death (Maastricht categories III and
IV12); and (5) high-risk history, such as multiple (>10 units) blood trans-
fusions or questionable history of aspiration. Donor lungs with estab-
lished pneumonias, severe mechanical lung injury defined by gross
contusions in more than 1 lobe, and evidence of aspiration of gastric con-
tents were excluded.
Recipients
All recipients for single or bilateral transplantation and retransplanta-
tion were considered EVLP eligible. Recipients on extracorporeal life
support (ECLS) before transplantation were excluded from this analysis
because they have an increased risk for primary graft dysfunctionThe Journal of Thoracic and Car(PGD) and have longer stays in the hospital compared with other
recipients.13
Ex Vivo Lung Perfusion Logistics
Donor lung offers are made to our clinical lung transplant program
through our regional organ procurement organization. Assessments of po-
tential donor lungs are made on the basis of the usual constellation of clin-
ical factors, such as history, P/F, bronchoscopic examination, radiologic
assessment, and direct examination of the organ during the procurement
procedure. Donor lungs considered to be high risk are selected for EVLP
only after complete assessment of the lungs by our team at the donor hos-
pital. From September 2008 to January 2010, all DCD lungs were subjected
to EVLP before LTx as part of the human ex vivo perfusion trial.9 Since
then, DCD lungs are subjected to EVLP at the discretion of the operating
surgeon on call. In general, if DCD lungs meet standard criteria and time
fromwithdrawal of life support therapy to cardiac arrest is less than 60min-
utes, direct transplantation is considered.
Once accepted for EVLP, donor lungs were transported to our center and
perfused in the EVLP system located in a sterile operating room environ-
ment. Approval for this EVLP study was obtained from our institutional
ethics review board and by Health Canada (#9427-V0689/1-21C, Control
#137622). All recipients receiving lungs after EVLP previously gave con-
sent. They were also informed of the EVLP procedure before LTx.
Ex Vivo Lung Perfusion Technique
The circuit was primed with 2 liters of Steen Solution (XVIVO, Vitro-
life). This solution is a buffered dextran containing an extracellular-type so-
lutionwith an optimized colloid osmotic pressure developed specifically for
EVLP. In addition, 500 mg of methylprednisolone (Solu-Medrol; Sandoz
Canada, Boucherville, Canada), 500 mg of imipenem/cilastatin (Primaxin;
Merck, Whitehouse Station, NJ), and 3000 IU of heparin (Organon, Can-
ada) were added to the perfusate. After the first hour of EVLP, 500 mL of
circulated perfusate was removed and replenished with 500 mL of fresh so-
lution. Subsequently, 250mLwas exchanged every hour until the end of the
procedure. No blood products were added to the circuit.
The detailed acellular EVLP technique has been described.14-16 In brief,
after the lungs were transferred to the XVIVO chamber, the pulmonary
artery and left atrium specifically designed cannulas (XVIVO) were
connected to the circuit and anterograde flow was started at 150 mL/min
with the perfusate at room temperature. The temperature of the perfusate
was then gradually increased to 37C. When 32C was reached (usually
>30 minutes), ventilation was started and the perfusate flow rate was
gradually increased. The flow of gas used to deoxygenate and provide
carbon dioxide to the inflow perfusate via a gas exchange membrane was
then initiated at 1 L/min. We used 40% of the estimated donor cardiac
output as the target maximum maintenance perfusate flow rate to perfuse
both lungs. Mean pulmonary artery pressures were maintained between 7
and 15 mm Hg. A positive left atrium pressure was maintained between
3 and 5 mm Hg by adjusting the height of the hard-shell reservoir. A pro-
tective mode of mechanical ventilation was applied using a tidal volume of
7 mL/kg (based on donor ideal body weight) at 7 breaths/min, positive end-
expiratory pressure of 5 cmH2O, and FIO2 of 21%. The lungs were recruited
with inspiratory holds to a peak airway pressure of 20 cmH2O every hour.
For the evaluation of lung function, FIO2 was increased to 100%, tidal vol-
umes were increased to 10 mL/kg, and respiratory rate was increased to 10
breaths/min for 5 minutes. The pH, pCO2, electrolytes, and glucose were
maintained at physiologic levels in the perfusate.
At the end of EVLP, the lung block was cooled down in the circuit to
10C in a 10-minute period. Thereafter, perfusion and ventilation were
stopped (FIO2 was increased to 50% for lung storage), and the trachea
was clamped to maintain the lungs in an inflated state. The lungs were
then statically preserved at 4C in Perfadex until transplantation.
Lung function was evaluated every hour as follows: P/F in pulmonary
vein effluent (mm Hg), pulmonary artery pressure (mm Hg), lung dynamicdiovascular Surgery c Volume 144, Number 5 1201
TABLE 1. Donor, recipient, and transplantation characteristics
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Xcompliance (mL/cmH2O), and peak airway pressures (cmH2O). Plain
ex vivo lung x-rays and flexible bronchoscopy were performed at 1 hour
and 3 hours of EVLP.
Study End Points
The primary end point was International Society for Heart and Lung
Transplantation PGD grade 317 (P/F< 200 mm Hg) at 72 hours post-
LTx. Secondary end points were need for ECLS, time of mechanical
ventilation, ICU and hospital lengths of stay, incidence of bronchial com-
plications requiring intervention, 30-day mortality, and proportional
survival.
Statistical Analysis
All statistics were calculated with GraphPad Prism 5 (GraphPad Soft-
ware Inc, La Jolla, Calif). Results are given as median and ranges. A non-
parametric Mann–Whitney test was performed to compare numeric data,
and a Fisher exact test was used for categoric data. For differences in
lung P/Fs over 4 hours of EVLP within the same group at several time
points, repeated-measures analysis of variancewas used. Two-way analysis
of variance was used for comparison of ex vivo P/Fs between the 2 groups.
Kaplan–Meier curves were used for survival plots, and the log-rank test
was used to compare proportional survival from EVLP and controls.
RESULTS
From September 2008 to December 2011 (39 months),
317 LTxs were performed at the University of Toronto.
Fourteen transplants were performed in patients bridged
with ECLS and therefore excluded from this analysis. A to-
tal of 253 consecutive transplants were performed after con-
ventional assessment and preservation (controls), and 50
transplants were performed after EVLP assessment/treat-
ment (22 [44%] were Maastricht category III DCDs12 and
28 [56%] were brain death donors [BDDs]) (Figure 1).
Eight additional donor lungs were subjected to EVLP but
were not transplanted because they did not meet functional
criteria for transplantation. Of these 8 rejected lungs, 4 were
fromBDDs and 4 were fromDCDs, with a range of donor P/
F from 92 to 420 mm Hg, and aspiration was detected dur-
ing more detailed examination of the airways during EVLP
bronchoscopy in 2 cases. All BDDs were considered high
risk according to donor selection criteria. ApproximatelyFIGURE 1. Study diagram. ECLS, Extracorporeal life support; EVLP,
ex vivo lung perfusion; Tx, transplantation.
1202 The Journal of Thoracic and Cardiovascular Surhalf of the DCDs (12/22) had acceptable P/Fs, but they
were included in the EVLP arm as part of inclusion criteria
during our initial trial.9
Baseline donor lung characteristics were significantly
different in the EVLP group compared with controls
(Table 1). Donor lungs in the EVLP group had significantly
worse gas exchange function (median best donor P/F, 334
mm Hg [range, 143-532 mm Hg] vs 452 mm Hg [range,
256-590 mm Hg] in controls; P ¼ .0001) and more abnor-
malities on chest x-rays (67% vs 45%, P ¼ .001).
Ex vivo gas exchange function, peak airway pressure,
and dynamic compliance were significantly better in lungs
used after EVLP compared with lungs that were rejected af-
ter EVLP (Figure 2). The median P/F ratios in the donor and
after 1 hour and 4 hours of ex vivo perfusion were 334 mm
Hg, 478 mm Hg, and 513 mm Hg, respectively (P ¼ .0001;
donor P/F vs 1 hour and 4 hours). X-ray of the lung block
was performed at 1 hour and 3 hours of EVLP. Lungs se-
lected for transplantation demonstrated stable or improved
x-ray findings, such as reduced pulmonary edema.
Table 1 summarizes the recipient and transplantation
characteristics. There were no significant differences be-
tween the 2 groups with regard to relevant baseline charac-
teristics, such as age or medical diagnosis. Medical
diagnoses of patients receiving EVLP lungs were emphy-
sema (n ¼ 19), pulmonary fibrosis (n ¼ 14), cystic fibrosis
(n ¼ 12), and other (n ¼ 5).
EVLP recipients tended to have less PGD 3 at 72 hours
after LTx (EVLP 2% vs control 8.5%; P ¼ .14) (Table
2). One patient (2%) in the EVLP group and 7 patients
(2.7%) in the control group required ECLS for PGD
(P ¼ 1.00). The median time to extubation and ICU and
hospital lengths of stay were 2, 4, and 20 days, respectively,
in the EVLP group and 2, 4, and 23 days, respectively, in the
control group (P>.05). The incidence of bronchial compli-
cations requiring intervention was the same in both groupsDonor variable
EVLP
(n ¼ 50)
Controls
(n ¼ 253)
P
value
Age (y) 45 45 .52
DCD (%) 44 5.1 .0001
Best P/F ratio (mm Hg) 334 452 .0001
Chest x-ray abnormalities (%) 67 45 .001
Positive BAL cultures (%) 70 55 .05
Recipient variable
Age 56 56 .68
Diagnosis of pulmonary fibrosis or
PAH (%)
32 38.7 .42
Transplantation variable
Bilateral (%) 76 88 .04
Retransplantation (%) 2 3.5 1.00
Cardiopulmonary bypass (%) 30 39 .26
EVLP, Ex vivo lung perfusion; DCD, donation after cardiac death; P/F, PaO2/FIO2;
BAL, bronchoalveolar lavage; PAH, pulmonary arterial hypertension.
gery c November 2012
FIGURE 2. Lung function during EVLP in lungs used (n¼ 50) and rejected (n¼ 8) for transplantation. Gas exchange, peak airway pressure, and dynamic
compliance were significantly better in lungs used after EVLP compared with lungs that were rejected. No differences were observed in pulmonary artery
pressures. PAP, Pulmonary artery pressure; PawP, peak airway pressure; P/F, PaO2/FIO2; EVLP, ex vivo lung perfusion.
Cypel et al Cardiothoracic Transplantation(4%, P ¼ 1.00). Two of 50 patients (4%) died within 30
days in the EVLP group compared with 9 of 253 patients
(3.5%) in the control group (P ¼ 1.00). One-year survival
was 87% in the EVLP group and 86% in the control group
(P¼ 1.00), and 3-year survival was 70% in the EVLP group
and 72% in the control group (P ¼ .86) (Figure 3, A).
Causes of death in the EVLP group are shown in Table 3.
Because DCD lungs subjected to EVLP had better last do-
nor P/F ratio compared with the subgroup BDD lungs sub-
jected to EVLP (363 vs 285 mm Hg, P ¼ .02), a subgroupTABLE 2. Recipient outcomes in ex vivo lung perfusion and
conventional transplants
Variable
EVLP
(n ¼ 50)
Controls
(n ¼ 253)
P
value
PGD 3 at 72 h (%) 2 8.5 .14
ECLS (%) 2 2.7 1.00
Mechanical ventilation (d) .30
Median 2 2.2
Range 1-101 1-43
ICU stay (d) .32
Median 4 4.5
Range 1-100 1-257
Hospital stay (d) .11
Median 20 23
Range 7-156 1-299
30-d mortality (%) 4 3.5 1.00
Anastomotic stricture
requiring intervention (%)
4 4 1.00
EVLP,Ex vivo lung perfusion; PGD, primary graft dysfunction; ECLS, extracorporeal
life support; ICU, intensive care unit.
The Journal of Thoracic and Caranalysis was performed. No differences were observed in
the survival of recipients receiving lungs from either donor
type after EVLP (Figure 3, B). Likewise, no survival differ-
ences were observed in recipients receiving EVLP lungs for
which the donor P/F ratio was less than 300 mm Hg
(Figure 3, C).T
XDISCUSSION
Although the demand for LTx far outweighs the number
of donor lungs available, the use rate of potential donor or-
gans in LTx is the lowest among solid-organ transplanta-
tion, between 15% and 20%. The main reason for the
conservative donor lung selection is PGD, a clinical entity
that resembles acute lung injury and occurs within 72 hours
of transplantation.18 PGD can occur when an injured lung is
implanted into a recipient, and the condition remains a chal-
lenging clinical problem for which there is still no reliably
effective pharmacotherapy. Furthermore, there is a lack of
accurate donor lung assessment tools to predict whether
a given donor lung will function properly immediately after
transplantation.19 Lungs that appear ‘‘questionable’’ are of-
ten declined by transplant clinician, leading to wastage of
potentially usable donor lungs.20
This study reviewed our experience with normothermic
EVLP as a means to reevaluate the function and improve
the quality of injured donor lungs. Fifty transplants of 58
perfusions ultimately met ex vivo functional criteria and
were transplanted. This is the largest experience to date us-
ing clinical EVLP. After our initial clinical series, severaldiovascular Surgery c Volume 144, Number 5 1203
FIGURE 3. Proportional survival of EVLP and conventional transplants. A, No differences were observed in the 2 groups (P¼ .69). B, No differences were
observed in the survival of recipients receiving lungs from either donor types (BDDs or DCDs) after EVLP (P ¼ .71). C, Recipients who received EVLP
lungs in which the donor P/F ratio was less than 300 mmHg had similar outcomes compared with recipients who received donor lungs with a P/F ratio more
than 300 mm Hg (P ¼ .78). BDD, Brain death donor; DCD, cardiac death donor; EVLP, ex vivo lung perfusion; LTx, lung transplantation.
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X other centers have started the use of EVLP using the tech-
nique described by our group,14 and outcomes have been
encouraging demonstrating the reproducibility of the
procedure.
Donor lungs included in the study had impaired gas ex-
change or other concerning findings, such as evidence of bi-
lateral infiltrates on chest x-ray, clinical evidence of
pulmonary edema, and suspected aspiration, or concerning
history factors, such as multiple blood transfusions in the
context of trauma. All BDDs (n ¼ 28) were considered
high-risk donors and would not be transplanted without
the availability of EVLP. The remaining 22 donors were
from DCDs. We currently subject most DCD lungs to
EVLP assessment before LTx. Although small clinical1204 The Journal of Thoracic and Cardiovascular Surseries, including our own, have shown good outcomes after
DCD LTx21-27 without the use of EVLP, we still believe this
is a less predictable organ in regard to the development of
PGD. We would consider the use of DCD lungs even with
a 2-hour interval between withdrawal of life support to ar-
rest if they are reassessed with EVLP. This demonstrates
the impact that EVLP might have on lung use rates
even in a lung transplant center with an already high use
rate (30%-40%) of donor lungs from multiorgan donors.
We understand that the definition of ‘‘high-risk’’
donors varies from center to center and may be broader in
more ‘‘conservative’’ lung transplant centers than in more
‘‘aggressive’’ centers, but in either case, EVLP will give
clinicians in either setting the confidence to transplantgery c November 2012
TABLE 3. Causes of death in ex vivo lung perfusion recipients
Medical diagnosis Survival (d) Cause of death
COPD/emphysema 644 CGD
COPD/emphysema 771 Bacterial pneumonia
Cystic fibrosis 66 Cepacia sepsis
Pulmonary fibrosis 710 CGD
Retransplant 100 Fungus infection
Pulmonary fibrosis 17 Retroperitoneal hemorrhage
Pulmonary fibrosis 7 Gram sepsis
PPH 507 Bacterial pneumonia
Cystic fibrosis 52 Cepacia sepsis
Pulmonary fibrosis 101 Bacterial pneumonia
(bronchial stenosis)
COPD, Chronic obstructive pulmonary disease; CGD, chronic graft dysfunction;
PPH, primary pulmonary hypertension.
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T
Xmore lungs, using donors that are beyond their own ‘‘com-
fort zone’’ of use. EVLP likely added a 10% to 15% in-
crease in the number of transplants at our center in the
past 3 years, considering that this was the additional propor-
tion of lungs that would be discarded by our group if EVLP
was not available. Although the number of transplants var-
ied from 85 to 102 per year in these 3 years, the number of
multiorgan BDDs had actually decreased in our organ pro-
curement organization, and yet we were able to keep our
lung transplant numbers at a consistent level. Also of
note, in 2011, our 30-day mortality was only 2%, despite
performing transplantations in sicker recipients. We believe
EVLP has a role in that process because some extended
lungs for which we would push the limits in the past are
now first checked with EVLP for assurance of performance.
Although no specific EVLP P/F (cutoff) can be estab-
lished from this study to decide when a lung can be safely
transplanted after EVLP, P/F greater than 400 mm Hg and
stable pulmonary artery pressure, peak airway pressure,
and lung compliance during 4 hours of perfusion translates
into successful post-transplant outcomes. The significant
increase in the P/F ratio in the first hour of EVLP observed
by our group and by others is most likely a reflection of lung
recruitment and optimization of ventilation/perfusion
matching in the lung, and thus on its own should be inter-
preted with caution. To that end, we find that a perfusion
time of at least 3 hours is required before making a decision
on lung use. In the future, the use of lung specific bio-
markers will further assist in the precision of assessment
during EVLP. The increase of lactate in the perfusate did
not correlate with post-transplant outcomes.28
Despite EVLP lungs being more injured than conven-
tional transplants, they had low levels of PGD 3, only 2%
at 72 hours, compared with 8.5% in controls. Likewise,
time on mechanical ventilation, ICU stay, and length of hos-
pitalization were acceptable and comparable to those of
conventional transplants. One-year survival was 87% per-
cent in the EVLP group compared with 86% in controls.
We also stratified the EVLP survival analysis in recipientsThe Journal of Thoracic and Carreceiving lungs from BDD versus DCD and in recipients re-
ceiving lungs in which the best donor P/F was less than 300
mmHg versus more than 300mmHg. Again, no differences
were observed in these 2 subgroups.
Although no direct cause of death could be attributed to
EVLP (Table 3), 1 patient had anastomotic stricture leading
ultimately to bacterial pneumonia and death. Although we
cannot rule out EVLP as a contributing factor for this
specific airway complication, the general incidence of
anastomotic complications was low in this cohort of
patients (4%).CONCLUSIONS
The present study demonstrates that 4-hour normother-
mic acellular EVLP is safe and provides similar outcomes
compared with conventionally selected and transplanted
donor lungs. It is a useful technique to improve and reassess
the function of high-risk donor lungs, increasing the safe
use of lungs. In the future, perhaps every organ will go
through an EVLP ‘‘check’’ and reconditioning before trans-
plantation; however, the benefit of this concept needs to be
demonstrated in a randomized clinical trial. The present
study also provides the basis for further clinical studies us-
ing EVLP as a platform for more advanced targeted phar-
macologic and molecular therapeutic strategies to treat
specific donor lung injuries ex vivo.16 Ultimately, this opens
the door for an approach of ‘‘personalized medicine for the
organ’’—the opportunity to diagnose and specifically treat
or repair the donor organ to optimize outcome after
transplantation.References
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Dr R. Duane Davis (Durham, NC). First a disclosure. We are
being supported by Vitrolife. They funded the US trial.
Marcelo, congratulations on an excellent presentation. You and
your colleagues at the University of Toronto have again demon-
strated the safety and efficacy of using EVLP to enable the trans-
plantation of lungs that would previously not have been used by
your group. In the United States, lung disease is the fourth most
common cause of death; it accounts for approximately 125,000
deaths per year. We perform approximately 2000 lung transplants
per year. So you could say there is an approximate 122,000 short-
fall in the number of transplants that potentially could be done. Ob-
viously that is a bit of an overestimation; not of all those would be
appropriate candidates. But using this technology, we may start to
be able to apply LTx more effectively for societal needs. As you
have mentioned, only approximately 17% of the lungs in the
United States from consented donors actually yield lungs for1206 The Journal of Thoracic and Cardiovascular Surtransplant. So my questions are going to be primarily focused on
the overall impact that EVLP may have on LTx.
In your group’s experience, 86% of the lungs treated with EVLP
were subsequently transplanted, and they now account for approx-
imately 20% of the overall transplants you perform at Toronto.
However, this yield seems to be substantially different than what
we are seeing in the US trial. Currently, approximately 54% of
lungs (1 of 2) treated with EVLP are being transplanted. This
is fairly consistent with data from the United Kingdom and other
countries.
What do you think are the differences? Are you using lungs that
we would have conventionally used or lungs that may actually fit
better with the operating room schedule, that is, operations are oc-
curring at 2 AM, and this allows you to do it during the daytime?
Dr Cypel. That is an interesting point. To be relatively direct
about that, none of these perfusions were performed because we
would be able to perform transplantations at a less disruptive
time. It is an interesting concept and totally feasible, because we
have shown that we can safely keep these organs 12 hours in the
system without any added injury. But that was not the case in
this specific population.
The main difference in our higher use rates compared with the
other groups that more recently started with EVLP is based on the
experience that our group has with the procedure. We have exten-
sive laboratory research, performing EVLP in more than 100 large
animals and in rejected human lungs before starting a clinical trial,
and this is different than the current scenario at other centers. That
is part of the answer. I also think it is related to the donor selection.
More recently, we have pushed the limits further; consequently, we
have used fewer lungs after EVLP. I think it depends on the donor
selection criteria.
Dr Davis. Although the overall cohort of patients receiving
EVLP lungs had essentially identical outcomes to those of patients
receiving conventional lungs, the patients receiving EVLP lungs
from the DCDs had an approximate 20% 6-month mortality. Al-
though this is not statistically significant, it does raise some con-
cern, particularly when we are starting to think about going into
the uncontrolled DCD or the Maastricht categories 1 and 2, where
we could substantially increase the donor pool.
Does this raise concerns, and have you looked at things such as
warm ischemic time in these DCDs to try to get an early signal?
Although there are few events, it would be nice to know if there
are things that we should avoid in the DCD population.
Dr Cypel.We have looked at the causes of death in these 4 re-
cipients who received DCD lungs after EVLP and died in the first 6
months. Two of those were patients who had a diagnosis of cepa-
cia-positive cystic fibrosis and ultimately died of cepacia sepsis af-
ter being discharged from the hospital. The third patient had
a massive retroperitoneal hematoma after being anticoagulated
for atrial fibrillation, and the fourth patient died of gram-negative
sepsis, so the deaths were not really related to the quality of the
graft. We are happy with our low incidence of PGD after transplan-
tation using DCD lungs.
In regard to your question of the interval of time from with-
drawal of life-support therapies to cardiac arrest, there was really
no difference, but as you mentioned, I think the numbers are small.
The Australian experience has shown that perhaps there is a signal
there, but I think when we put all the data together from thegery c November 2012
Cypel et al Cardiothoracic TransplantationInternational Society of Heart and Lung Transplantation, we will
be able to discriminate that better.
Dr Davis. My final question is basically to look in the crystal
ball. We are currently performing 2000 lung transplants. You say
that approximately 20% of the lungs you use are being treated
nowwith EVLP, but you actually have been static at approximately
100 lung transplants per year. So even though you have this new
technology, it has not seemed to increase the volume of transplants
you are performing. The goal in the United States is to achieve
40% to 50% use or to double or triple the number of transplants.
With EVLP as it is now, where do you think it is going to actu-
ally drive the number of transplants in the United States without
doing things such as gene therapy or other resuscitation therapies
on the lungs?The Journal of Thoracic and CarDr Cypel. For the first part of the question, our numbers have
been stable at 100 in the last 2 years; the organ donation rates in
our organ procurement organization have decreased in the last 2
years, and all solid-organ transplant numbers have decreased in
our institution, and we are able to keep our number stable. I think
it did make a contribution on that end.
The major contribution of EVLP will not be for the large num-
ber of transplant centers with high use rates (eg, Duke or Toronto)
and that already use 40% of the organs. Their margin of increase is
not that large, but if we look at the majority of lung transplant cen-
ters that use less than 10% of the offered lungs, that is where we
can make a major impact, increasing the number of organs
available.
Dr Davis. Again, congratulations.diovascular Surgery c Volume 144, Number 5 1207
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